Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Astellas to Promote Vesicare Independently in the US
February 28, 2011
- Record Number of New AIDS Patients in 2010: Surveillance Committee
February 28, 2011
- Nippon Shinyaku Licenses Gaslon N to Lee's Pharmaceutical in China
February 28, 2011
- Janssen Launches Once-Daily Fentanyl Patch
February 21, 2011
- No Differences in Impurity Contents in 6 Cisplatin Products: NIHS Study Group
February 21, 2011
- Astellas Licenses Fidaxomicin from Optimer
February 21, 2011
- Sawai: First 3-Qtr Sales, Profits Show Double-Digit Growth
February 21, 2011
- Astellas Creates Sales Subsidiary in Australia
February 21, 2011
- PHARMA JAPAN Lexicon: 47
February 21, 2011
- Santen Allies with DBJ
February 21, 2011
- Korosho to Review Current Risk Classification of OTC Drugs
February 21, 2011
- Otsuka Holds Sufficient Stock of IFN from Hayashibara
February 21, 2011
- AZ Stops Multinational PIII Trial of Zibotentan
February 21, 2011
- Astellas Withdraws Application for Darexaban in Japan
February 21, 2011
- Toho Starts New OTC Drugs Sales System Jointly with eHealthcare
February 21, 2011
- Gov't-Industry Dialogue to Resume in March
February 21, 2011
- Introduce “Compendium System”to Solve Problems of Off-label Use: Dr Fujiwara of NCC Hospital
February 21, 2011
- Halaven Approved in Singapore: Eisai
February 21, 2011
- Domestic Production of Drugs Up 3%, Highest in 10 Years
February 21, 2011
- PAFSC to Review Rivastigmine, Edoxaban, Epoetin β Pegol
February 21, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…